100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
CAMBRIDGE, Mass., Feb. 02, 2016 -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today announced that Thomas Mathers, Chief Executive Officer, will present a corporate overview at the BIO CEO & Investor Conference, being held in New York City February 8-9.
| BIO CEO & Investor Conference -- CoLucid Presentation Details | |||
| Date: | Tuesday, February 9 | ||
| Time: | 2:30pm Eastern Time | ||
| Location: | Waldorf Astoria, Conrad Room | ||
| Webcast: | http://www.veracast.com/webcasts/bio/ceoinvestor2016/45227430457.cfm | ||
About CoLucid Pharmaceuticals, Inc.
CoLucid was founded in 2005 and is developing oral lasmiditan for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.
Thomas Mathers Chief Executive Officer CoLucid Pharmaceuticals, Inc. (857) 285-6494 Hans Vitzthum Managing Director LifeSci Advisors, LLC. (212) 915-2568
